科伦药业：子公司注射用比阿培南/氯化钠注射液获得药品注册批准

Core Viewpoint - Kolon Pharmaceutical's subsidiary has received drug registration approval for its injectable product, marking a significant milestone in the domestic pharmaceutical market [1] Company Summary - Kolon Pharmaceutical (002422.SZ) announced that its subsidiary, Hunan Kolon Pharmaceutical Co., Ltd., has obtained approval from the National Medical Products Administration for its injectable drug "Injectable Biapenem/Sodium Chloride Injection" [1] - This product is the first of its kind in China to be approved in a dual-chamber bag packaging format [1] - The drug features a broad antibacterial spectrum, stability against β-lactamase, and strong antibacterial activity, while exhibiting lower nephrotoxicity and central nervous system toxicity [1]